As of June 21, 2025, Applied Therapeutics Inc (APLT) reports a Net Margin of -23214.07%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Applied Therapeutics Inc's Net Margin
Over recent years, Applied Therapeutics Inc's Net Margin has shown limited historical data. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -23214.07% |
| 2023-12-31 | -1198.47% |
This trend highlights how Applied Therapeutics Inc manages its overall profitability and cost control over time.
Comparing Applied Therapeutics Inc's Net Margin to Peers
To better understand Applied Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Applied Therapeutics Inc (APLT) | -23214.07% |
| Aptose Biosciences Inc (APS.TO) | 4175.00% |
| IVERIC bio Inc (ISEE) | 54.38% |
| Selecta Biosciences Inc (SELB) | 31.94% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
Compared to its competitors, Applied Therapeutics Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.